Cand.med Elise Thoresen Sletten disputerer for ph.d.-graden i helsevitenskap og vil offentlig forsvare avhandlingen:
“Significance of progestin therapy in endometrial proliferative diseases”
Kort sammendrag av avhandlingen:
Approximately 3% of women are diagnosed with uterine cancer during their lifetime. Most cases develop from a precursor lesion denoted endometrial hyperplasia (EH), a common diseases in women of all ages.
In the present thesis all women diagnosed with EH became disease-free after 6 months of therapy with Jaydess, an intrauterine system originally developed as a contraceptive. Jaydess is releasing the growth inhibitory hormone levonorgestrel and due to its intrauterine application the local effect in the uterus is strong combined with few systemic side effects. These results introduce Jaydess as a new and effective therapy option for women diagnosed with EH.
We have also demonstrated that uterine expression of progesterone receptors in women with EH can be useful in selecting women with high risk of relapse of the disease after successful therapy. Thus, our findings might have implications for tailoring individualized therapy and follow-up strategies in women with EH.
Veiledere
Hovedveileder professor Anne Ørbo
Biveileder førsteamanuensis Anne Beate Vereide
Bedømmelseskomiteen
Dr. med Bjørn Hagen, NTNU – 1. opponent
Dosent Pernilla Dahm-Kähler, Sahlgrenska Universitetssjukhuset, Sverige – 2. opponent
Førsteamanuensis Marit Helene Hansen, UiT – Norges arktiske universitet – leder av komité
Disputasleder
Professor Christine Rinaldo, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, Universitetet i Tromsø – Norges arktiske universitet
Prøveforelesning over oppgitt emne holdes kl. 10.15, samme sted: “Risikogruppe klassifisering av pasienter med endometriecancer.
Diagnostiske metoder.
Betydning for prognose og valg av behandling.”